Engineering biomaterials for next-generation cancer immunotherapy: From cell manufacturing to in vivo modulation
Cell Biomaterials · 2026-05 · 2 (5) · 100380
DOI: 10.1016/j.celbio.2026.100380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biomaterials, 2026-05. Verfasst von Zeyang Liu und 9 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 392 Literaturangaben. Gefördert von: Congressionally Directed Medical Research Programs, National Institutes of Health, University of California, Los Angeles.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Congressionally Directed Medical Research Programs
- National Institutes of Health
- University of California, Los Angeles
- California Institute for Regenerative Medicine
Zitieren
APA
Liu, Z., Li, Y., Yang, Y., Shen, X., Zhu, E., Nan, H., Wang, S., Lin, J., Yang, L., & Li, S. (2026). Engineering biomaterials for next-generation cancer immunotherapy: From cell manufacturing to in vivo modulation. Cell Biomaterials, 2(5), 100380. https://doi.org/10.1016/j.celbio.2026.100380
Vancouver
Liu Z, Li Y, Yang Y, Shen X, Zhu E, Nan H, et al. Engineering biomaterials for next-generation cancer immunotherapy: From cell manufacturing to in vivo modulation. Cell Biomaterials. 2026;2(5):100380. doi:10.1016/j.celbio.2026.100380
BibTeX
@article{Liu2026,
author = {Liu, Zeyang and Li, Yan-Ruide and Yang, Youcheng and Shen, Xinyuan and Zhu, Enbo and Nan, Haochen and Wang, Shubing and Lin, Jason and Yang, Lili and Li, Song},
title = {Engineering biomaterials for next-generation cancer immunotherapy: From cell manufacturing to in vivo modulation},
journal = {Cell Biomaterials},
year = {2026},
volume = {2},
number = {5},
pages = {100380},
doi = {10.1016/j.celbio.2026.100380}
}
EUVIMED